• Je něco špatně v tomto záznamu ?

Efficacy of prehospital administration of fibrinogen concentrate in trauma patients bleeding or presumed to bleed (FIinTIC): A multicentre, double-blind, placebo-controlled, randomised pilot study

B. Ziegler, M. Bachler, H. Haberfellner, C. Niederwanger, P. Innerhofer, T. Hell, M. Kaufmann, M. Maegele, U. Martinowitz, C. Nebl, E. Oswald, H. Schöchl, B. Schenk, M. Thaler, B. Treichl, W. Voelckel, I. Zykova, C. Wimmer, D. Fries, FIinTIC study group

. 2021 ; 38 (4) : 348-357. [pub] 20210401

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc21018907

BACKGROUND: Trauma-induced coagulopathy (TIC) substantially contributes to mortality in bleeding trauma patients. OBJECTIVE: The aim of the study was to administer fibrinogen concentrate in the prehospital setting to improve blood clot stability in trauma patients bleeding or presumed to bleed. DESIGN: A prospective, randomised, placebo-controlled, double-blinded, international clinical trial. SETTING: This emergency care trial was conducted in 12 Helicopter Emergency Medical Services (HEMS) and Emergency Doctors' vehicles (NEF or NAW) and four trauma centres in Austria, Germany and Czech Republic between 2011 and 2015. PATIENTS: A total of 53 evaluable trauma patients aged at least 18 years with major bleeding and in need of volume therapy were included, of whom 28 received fibrinogen concentrate and 25 received placebo. INTERVENTIONS: Patients were allocated to receive either fibrinogen concentrate or placebo prehospital at the scene or during transportation to the study centre. MAIN OUTCOME MEASURES: Primary outcome was the assessment of clot stability as reflected by maximum clot firmness in the FIBTEM assay (FIBTEM MCF) before and after administration of the study drug. RESULTS: Median FIBTEM MCF decreased in the placebo group between baseline (before administration of study treatment) and admission to the Emergency Department, from a median of 12.5 [IQR 10.5 to 14] mm to 11 [9.5 to 13] mm (P = 0.0226), but increased in the FC Group from 13 [11 to 15] mm to 15 [13.5 to 17] mm (P = 0.0062). The median between-group difference in the change in FIBTEM MCF was 5 [3 to 7] mm (P < 0.0001). Median fibrinogen plasma concentrations in the fibrinogen concentrate Group were kept above the recommended critical threshold of 2.0 g l-1 throughout the observation period. CONCLUSION: Early fibrinogen concentrate administration is feasible in the complex and time-sensitive environment of prehospital trauma care. It protects against early fibrinogen depletion, and promotes rapid blood clot initiation and clot stability. TRIAL REGISTRY NUMBERS: EudraCT: 2010-022923-31 and ClinicalTrials.gov: NCT01475344.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21018907
003      
CZ-PrNML
005      
20210830100459.0
007      
ta
008      
210728s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1097/EJA.0000000000001366 $2 doi
035    __
$a (PubMed)33109923
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Ziegler, Bernhard $u From the Department of Anaesthesiology, Perioperative Medicine and General Intensive Care Medicine, Paracelsus Medical University, Salzburg (BZ), Department of General and Surgical Critical Care Medicine, (MB, BS, DF ), Department of Anaesthesiology and Intensive Care Medicine (HH, PI, MK, EO, MT, BT), Department of Pediatrics, Pediatrics I, Intensive Care Unit, Medical University of Innsbruck, Innsbruck (CN), Department of Mathematics, Faculty of Mathematics, Computer Science and Physics, University of Innsbruck, Technikerstrasse, Austria (TH), Department of Trauma and Orthopedic Surgery, Cologne-Merheim Medical Center (CMMC), University Witten/Herdecke (UW/H), Campus Cologne-Merheim, Cologne, Germany (MM), Institute of Thrombosis and Haemostasis and the National Haemophilia Centre, The Chaim Sheba Medical Centre, Tel Hashomer, Israel (UM), Sportclinic Zillertal GmbH, Mayrhofen, Austria (CN), Department of Anaesthesiology and Intensive Care Medicine, AUVA Trauma Centre Salzburg, Academic Teaching Hospital of the Paracelsus Medical University, Salzburg, Austria (HS, WV), Department of Anesthesiology and Intensive Care, Liberec Regional Hospital, Liberec, Czech Republic (IZ), Christophorus 14, Niederöblarn, Austria (CW)
245    10
$a Efficacy of prehospital administration of fibrinogen concentrate in trauma patients bleeding or presumed to bleed (FIinTIC): A multicentre, double-blind, placebo-controlled, randomised pilot study / $c B. Ziegler, M. Bachler, H. Haberfellner, C. Niederwanger, P. Innerhofer, T. Hell, M. Kaufmann, M. Maegele, U. Martinowitz, C. Nebl, E. Oswald, H. Schöchl, B. Schenk, M. Thaler, B. Treichl, W. Voelckel, I. Zykova, C. Wimmer, D. Fries, FIinTIC study group
520    9_
$a BACKGROUND: Trauma-induced coagulopathy (TIC) substantially contributes to mortality in bleeding trauma patients. OBJECTIVE: The aim of the study was to administer fibrinogen concentrate in the prehospital setting to improve blood clot stability in trauma patients bleeding or presumed to bleed. DESIGN: A prospective, randomised, placebo-controlled, double-blinded, international clinical trial. SETTING: This emergency care trial was conducted in 12 Helicopter Emergency Medical Services (HEMS) and Emergency Doctors' vehicles (NEF or NAW) and four trauma centres in Austria, Germany and Czech Republic between 2011 and 2015. PATIENTS: A total of 53 evaluable trauma patients aged at least 18 years with major bleeding and in need of volume therapy were included, of whom 28 received fibrinogen concentrate and 25 received placebo. INTERVENTIONS: Patients were allocated to receive either fibrinogen concentrate or placebo prehospital at the scene or during transportation to the study centre. MAIN OUTCOME MEASURES: Primary outcome was the assessment of clot stability as reflected by maximum clot firmness in the FIBTEM assay (FIBTEM MCF) before and after administration of the study drug. RESULTS: Median FIBTEM MCF decreased in the placebo group between baseline (before administration of study treatment) and admission to the Emergency Department, from a median of 12.5 [IQR 10.5 to 14] mm to 11 [9.5 to 13] mm (P = 0.0226), but increased in the FC Group from 13 [11 to 15] mm to 15 [13.5 to 17] mm (P = 0.0062). The median between-group difference in the change in FIBTEM MCF was 5 [3 to 7] mm (P < 0.0001). Median fibrinogen plasma concentrations in the fibrinogen concentrate Group were kept above the recommended critical threshold of 2.0 g l-1 throughout the observation period. CONCLUSION: Early fibrinogen concentrate administration is feasible in the complex and time-sensitive environment of prehospital trauma care. It protects against early fibrinogen depletion, and promotes rapid blood clot initiation and clot stability. TRIAL REGISTRY NUMBERS: EudraCT: 2010-022923-31 and ClinicalTrials.gov: NCT01475344.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    12
$a urgentní zdravotnické služby $7 D004632
650    12
$a fibrinogen $7 D005340
650    _2
$a lidé $7 D006801
650    _2
$a pilotní projekty $7 D010865
650    _2
$a prospektivní studie $7 D011446
651    _2
$a Rakousko $7 D001317
651    _2
$a Česká republika $7 D018153
651    _2
$a Německo $7 D005858
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Bachler, Mirjam
700    1_
$a Haberfellner, Hubert
700    1_
$a Niederwanger, Christian
700    1_
$a Innerhofer, Petra
700    1_
$a Hell, Tobias
700    1_
$a Kaufmann, Marc
700    1_
$a Maegele, Marc
700    1_
$a Martinowitz, Uriel
700    1_
$a Nebl, Carolin
700    1_
$a Oswald, Elgar
700    1_
$a Schöchl, Herbert
700    1_
$a Schenk, Bettina
700    1_
$a Thaler, Markus
700    1_
$a Treichl, Benjamin
700    1_
$a Voelckel, Wolfgang
700    1_
$a Zykova, Ivana
700    1_
$a Wimmer, Christine
700    1_
$a Fries, Dietmar
710    2_
$a FIinTIC study group
773    0_
$w MED00001596 $t European journal of anaesthesiology $x 1365-2346 $g Roč. 38, č. 4 (2021), s. 348-357
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33109923 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100459 $b ABA008
999    __
$a ok $b bmc $g 1689865 $s 1139353
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 38 $c 4 $d 348-357 $e 20210401 $i 1365-2346 $m European journal of anaesthesiology $n Eur J Anaesthesiol $x MED00001596
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...